Business Context and Reporting Period
Company: Wearable Devices Ltd. (WLDS)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: An Israeli growth company developing non-invasive neural input interfaces (Mudra technology) for controlling digital devices via subtle finger movements. The company operates a "push-pull" strategy targeting both B2B (licensing to consumer electronics manufacturers) and B2C markets (selling the Mudra Band for Apple Watch and the Mudra Link universal wristband).
Key Developments: The company completed multiple reverse share splits (1-for-20 in Oct 2024, 1-for-4 in Mar 2025, and 1-for-3 in Mar 2026) to maintain Nasdaq compliance. It launched the Mudra Experience Studio in February 2026 to support AI developers.
Key Financial Metrics
| Metric (in thousands USD) | 2025 | 2024 |
|---|---|---|
| Revenues | $647 | $522 |
| Cost of Revenues | $(594) | $(362) |
| Impairment of Inventory | $(201) | $(75) |
| Gross Profit (Loss) | $(148) | $85 |
| Operating Loss | $(8,332) | $(7,820) |
| Net Loss | $(8,107) | $(7,879) |
| Cash and Cash Equivalents (Year End) | $6,500 | $3,089 |
| Short-term Deposits | $11,922 | $862 |
| Accumulated Deficit | $(37,209) | $(29,102) |
Liquidity: The company reported a net increase in cash of $3.4 million in 2025, driven primarily by $20.9 million in financing activities (equity offerings and warrant exercises). Management believes existing cash is sufficient to fund operations through the end of 2027.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 24% to $647,000, primarily driven by sales of the B2C Mudra Link product.
- Gross Margin Deterioration: The company shifted from a gross profit of $85,000 in 2024 to a gross loss of $(148,000) in 2025. This was caused by a 64% increase in cost of revenues and a significant increase in inventory impairment (from $75k to $201k) due to obsolete inventory write-offs.
- Operating Expenses:
- R&D: Increased 18% to $3.5 million, driven by higher share-based compensation and labor costs.
- Sales & Marketing: Decreased 12% to $1.85 million, largely due to the termination of the former Executive Vice President of U.S. Operations.
- G&A: Remained relatively flat at $2.83 million.
- Financing Activity: The company raised approximately $20.5 million in net proceeds during 2025 through registered direct offerings, best-efforts offerings, and warrant inducement transactions, primarily with Armistice Capital, LLC.
Guidance, Outlook, Risks, and Contingencies
Outlook: The company expects to continue incurring substantial operating losses. It plans to fund operations through equity issuances, warrant exercises, and Israeli government grants. No specific revenue guidance was provided.
Material Risks:
- Geopolitical Instability: Operations are based in Israel. The filing highlights significant risks related to ongoing conflicts with Hamas, Hezbollah, and Iran, which could disrupt operations, supply chains, and employee availability (reserve duty).
- Going Concern: While the 2025 financial statements were prepared on a going concern basis, the company has a history of recurring losses and negative cash flows. Future financing is not guaranteed.
- Competition: Major competitors (Meta, Apple) have launched or are developing competing neural input technologies (e.g., Meta Ray-Ban Neural Band, Apple Watch Double Tap).
- Regulatory/Grant Obligations: The company holds approximately $2.4 million in contingent liabilities related to royalties owed to the Israeli Innovation Authority (IIA) based on future sales of grant-funded products.
- Dilution: Significant dilution is expected from the exercise of outstanding warrants held by Armistice Capital, LLC, which could increase the share count by approximately 84% if fully exercised.
Investor Verification Checklist
- Inventory Valuation: Verify the rationale for the $201,000 inventory impairment and the remaining $778,000 inventory balance given the shift to a gross loss.
- Capital Structure: Confirm the impact of the 1-for-3 reverse split (effective March 11, 2026) on share count and warrant exercise prices.
- Concentration Risk: Assess the influence of Armistice Capital, LLC, which beneficially owns approximately 50.51% of outstanding shares as of March 2026.
- Geopolitical Exposure: Monitor the status of the conflict in Israel and its potential impact on the company's ability to manufacture and ship products.
- Government Grants: Review the terms of IIA grants to understand the royalty obligations (3.0%-3.5% of sales) and restrictions on manufacturing outside Israel.